DRREDDY · Healthcare
Dr. Reddy's Laboratories Ltd. reported revenue of ₹8,828 cr for July to September 2025, +9.8% on the year and +3.0% on the quarter. It is the highest quarterly revenue in the last 10 quarters on record. Over the last four quarters revenue comes to ₹34,309 cr, +14.0% on the four before.
Operating profit (EBITDA) was ₹2,010 cr, a margin of 22.8%, −306 bps on the year and −259 bps on the quarter. It is the narrowest margin of the last 8 quarters (range 22.8% to 28.0%). Operating costs grew +14.4%, faster than revenue at +9.8%, so operating profit grew less than sales.
Net profit was ₹1,337 cr, −0.4% on the year and −5.2% on the quarter, with earnings per share of ₹16.14. Profit before other income, one-offs and tax fell 11.7%, so 11 points of the headline growth came from outside the core business. The tax rate of 23% is in line with its recent average. Profit over the last four quarters totals ₹5,738 cr, +5.8% on the four before.
On earnings per share of ₹69.16 over the last four quarters, the stock at ₹1,229.70 trades at 17.8 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
Operating margin fell sharply on the year. Pricing, input costs, or mix?
EBITDA margin 22.8%, −306 bps on the year (−259 bps on the quarter).
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6,903 cr | ₹7,237 cr | ₹7,114 cr | ₹7,696 cr | ₹8,038 cr | ₹8,381 cr | ₹8,528 cr | ₹8,572 cr | ₹8,828 cr | ₹8,753 cr | ₹7,546 cr | ₹8,100 cr |
| YoY | — | — | — | +14% | +16% | +16% | +20% | +11% | +10% | +4% | −12% | −6% |
| EBITDA margin | 29.1% | 28.0% | 25.7% | 27.7% | 25.8% | 27.1% | 23.4% | 25.4% | 22.8% | 21.6% | 5.1% | 10.6% |
| Other income, % of PBT | 17% | 12% | 13% | 10% | 16% | 8% | 26% | 15% | 19% | 18% | 240% | 64% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | −11% | 21% |
| Net profit | ₹1,482 cr | ₹1,381 cr | ₹1,310 cr | ₹1,392 cr | ₹1,342 cr | ₹1,404 cr | ₹1,587 cr | ₹1,410 cr | ₹1,337 cr | ₹1,190 cr | ₹221 cr | ₹436 cr |
| YoY | — | — | — | −1% | −9% | +2% | +21% | +1% | −0% | −15% | −86% | −69% |
| Core profit YoY | — | — | — | +1% | +0% | +7% | +5% | −4% | −12% | −26% | −119% | −88% |
| EPS | ₹17.77 | ₹16.56 | ₹15.70 | ₹16.69 | ₹15.05 | ₹16.94 | ₹19.09 | ₹16.99 | ₹16.14 | ₹14.50 | ₹2.65 | ₹5.32 |
| Flags | · | · | · | ✓ | 1 | ✓ | 1 | ✓ | 1 | 1 | 4 | 2 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Dr. Reddy's Laboratories Ltd. reported revenue of ₹8,828 cr (+9.8% on the year) and net profit of ₹1,337 cr (−0.4% on the year) for July to September 2025.
Profit before other income, exceptional items and tax moved −11.7% on the year, against −0.4% for reported profit.
1 check raised a question: Operating margin fell sharply on the year. Pricing, input costs, or mix?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.